NHS England unveils new fund for innovative drugs
NHS England has unveiled its new Innovative Medicines Fund (IMF), to ensure patients have quick access to new “potentially life-saving” treatments.
The IMF will be used to accelerate the delivery of promising new drugs to patients who need them, building on the Reformed Cancer Drug Fund (CDF).
The new fund, however, will support patients with any condition, including those with rare and genetic diseases.
Through the IMF, these patients will have rapid access to the most clinically promising treatments when additional data is needed to support the final recommendations of the National Institute for Health and Care Excellence (NICE).
It will work the same as the CDF, giving NICE another option than making an immediate decision on routine availability on the NHS for new drugs.
‘Over the past year, NHS England has successfully negotiated deals for a range of new treatments, including drugs that could keep toddlers with spinal muscular atrophy walking on’ the world’s most expensive drug. world ”, as well as giving CF patients the option of the latest medications for their wasting disease. This new fund will build on these successes, offering hope to even more patients, ”said Simon Stevens, NHS chief executive.
In a statement, NHS England said the new initiative will receive £ 340million in funding, alongside the existing £ 340million CDF, meaning a total of £ 640million earmarked funding will be available to allow rapid access to innovative medicines.
Responding to the new IMF, ABPI Managing Director Richard Torbett said: “This government commitment is another important step towards improving access to new medicines for NHS patients.
“The fund can build on the success of the Cancer Drugs Fund and offer all patients the opportunity to benefit early from the most promising treatments, including those for the rarest diseases. It also sends a signal to the global pharmaceutical industry that the UK is committed to using new health technologies, which in turn could help boost investment in life sciences in the UK ”, he added.